Document is current
Any future updates will be listed below
-
Authors
Martyn, Emily https://orcid.org/0000-0003-4981-9298
Arenas-Pinto, Alejandro
Gilson, Richard https://orcid.org/0000-0002-9572-193X
Chandiwana, Nomathemba
Flanagan, Stuart
MacDonald, Douglas
Tsochatzis, Emmanuel A.
Venter, W. D. Francois https://orcid.org/0000-0002-4157-732X
Manne-Goehler, Jennifer
Matthews, Philippa C. https://orcid.org/0000-0002-4036-4269
-
Funding
Funding for this research was provided by:
Francis Crick Institute
The Francis Crick Institute, reference CC2223. NIHR University College London Biomedical Research Centre
PhD funding from the Francis Crick Institute.
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 5 January 2026
First Online: 8 May 2026
Competing interests
: P.C.M. has received funding support from GSK for a member of her team (2019-2023) outside the scope of this paper and has received payment from J&J for delivery of educational material during 2025. P.C.M. is clinical co-lead for the NIHR Health Informatics Collaborative for viral hepatitis and liver disease which has received GSK funding support, and is co-chair of the National Strategic Group for Viral Hepatitis. A.A.P. reports investigator-initiated study grants and/or personal fees from ViiV Healthcare, Gilead Sciences, and Jansen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), outside the scope of this paper. W.D.F.V.’s unit receives funding from the Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, Unitaid, Foundation for Innovative New Diagnostics (FIND), Merck and the Children’s Investment Fund Foundation (CIFF), has previously received funding from USAID, and received drug donations from ViiV Healthcare, Merck, J&J and Gilead Sciences for investigator-led clinical studies. This unit does investigator-led studies with Merck, J&J, Gilead, and ViiV, providing financial support, and is doing commercial drug studies for Merck and Novo, and performs evaluations of diagnostic devices for multiple biotech companies. Individually, W.D.F.V. receives honoraria for educational talks and advisory board membership for Gilead, ViiV, Mylan/Viatris, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi, Boehringer Ingelheim, Thermo-Fischer, and Virology Education. J.M.-G. is a site Principal Investigator for clinical trials with Viiv, GSK, Gilead, and Merck that fall outside the scope of this paper. N.C.’s unit receives research funding from Gilead and has received honoraria from Gilead Sciences and Novo Nordisk. R.G.’s unit receives research funding from Gilead, GSK, ViiV Healthcare, and Janssen. S.F. has received honoraria, conference support, and research grants from Viiv, Gilead, and MSD. Other authors have no competing interests to declare.
